{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:10:00Z","timestamp":1793851800801,"version":"4.6.1"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"8110","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2026,4,16]]},"DOI":"10.1038\/s41586-026-10149-8","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T16:03:09Z","timestamp":1772035389000},"page":"740-751","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumours"],"prefix":"10.1038","volume":"652","author":[{"given":"Luojia","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Renauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4538-6519","authenticated-orcid":false,"given":"Kaiyuan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5372-9696","authenticated-orcid":false,"given":"Josh","family":"Saskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3561-7495","authenticated-orcid":false,"given":"Liqun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok-Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Johnson-Noya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6165-2391","authenticated-orcid":false,"given":"Benedict","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paris","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binfan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Sferruzza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba","family":"Fooladi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6862-6635","authenticated-orcid":false,"given":"Daniel","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5376-9062","authenticated-orcid":false,"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Moliterno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2290-7055","authenticated-orcid":false,"given":"Murat","family":"Gunel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7159-5441","authenticated-orcid":false,"given":"Lei","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3819-5005","authenticated-orcid":false,"given":"Sidi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"10149_CR1","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/ni1582","volume":"9","author":"E Vivier","year":"2008","unstructured":"Vivier, E., Tomasello, E., Baratin, M., Walzer, T. & Ugolini, S. Functions of natural killer cells. Nat. Immunol. 9, 503\u2013510 (2008).","journal-title":"Nat. Immunol."},{"key":"10149_CR2","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3389\/fimmu.2020.00275","volume":"11","author":"A Ben-Shmuel","year":"2020","unstructured":"Ben-Shmuel, A., Biber, G. & Barda-Saad, M. Unleashing natural killer cells in the tumor microenvironment\u2014the next generation of immunotherapy?. Front. Immunol. 11, 275 (2020).","journal-title":"Front. Immunol."},{"key":"10149_CR3","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/ni.3518","volume":"17","author":"C Guillerey","year":"2016","unstructured":"Guillerey, C., Huntington, N. D. & Smyth, M. J. Targeting natural killer cells in cancer immunotherapy. Nat. Immunol. 17, 1025\u20131036 (2016).","journal-title":"Nat. Immunol."},{"key":"10149_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nrc.2015.5","volume":"16","author":"MG Morvan","year":"2016","unstructured":"Morvan, M. G. & Lanier, L. L. NK cells and cancer: you can teach innate cells new tricks. Nat. Rev. Cancer 16, 7\u201319 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"10149_CR5","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nri2604","volume":"9","author":"DH Raulet","year":"2009","unstructured":"Raulet, D. H. & Guerra, N. Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat. Rev. Immunol. 9, 568\u2013580 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"10149_CR6","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1016\/j.cell.2020.02.029","volume":"180","author":"A Crinier","year":"2020","unstructured":"Crinier, A., Narni-Mancinelli, E., Ugolini, S. & Vivier, E. SnapShot: natural killer cells. Cell 180, 1280\u20131280 (2020).","journal-title":"Cell"},{"key":"10149_CR7","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/ni1581","volume":"9","author":"LL Lanier","year":"2008","unstructured":"Lanier, L. L. Up on the tightrope: natural killer cell activation and inhibition. Nat. Immunol. 9, 495\u2013502 (2008).","journal-title":"Nat. Immunol."},{"key":"10149_CR8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","volume":"18","author":"JA Myers","year":"2021","unstructured":"Myers, J. A. & Miller, J. S. Exploring the NK cell platform for cancer immunotherapy. Nat. Rev. Clin. Oncol. 18, 85\u2013100 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10149_CR9","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41568-020-0272-z","volume":"20","author":"ND Huntington","year":"2020","unstructured":"Huntington, N. D., Cursons, J. & Rautela, J. The cancer\u2013natural killer cell immunity cycle. Nat. Rev. Cancer 20, 437\u2013454 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"10149_CR10","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/s41590-020-0728-z","volume":"21","author":"T Bald","year":"2020","unstructured":"Bald, T., Krummel, M. F., Smyth, M. J. & Barry, K. C. The NK cell\u2013cancer cycle: advances and new challenges in NK cell-based immunotherapies. Nat. Immunol. 21, 835\u2013847 (2020).","journal-title":"Nat. Immunol."},{"key":"10149_CR11","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1007\/s12015-021-10246-3","volume":"17","author":"R Elahi","year":"2021","unstructured":"Elahi, R., Heidary, A. H., Hadiloo, K. & Esmaeilzadeh, A. Chimeric antigen receptor-engineered natural killer (CAR NK) cells in cancer treatment; recent advances and future prospects. Stem Cell Rev. Rep. 17, 2081\u20132106 (2021).","journal-title":"Stem Cell Rev. Rep."},{"key":"10149_CR12","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s13287-021-02251-7","volume":"12","author":"F Marofi","year":"2021","unstructured":"Marofi, F. et al. Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy. Stem Cell Res. Ther. 12, 200 (2021).","journal-title":"Stem Cell Res. Ther."},{"key":"10149_CR13","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1038\/s41590-023-01659-y","volume":"24","author":"OK Dagher","year":"2023","unstructured":"Dagher, O. K. & Posey, A. D. Jr. Forks in the road for CAR T and CAR NK cell cancer therapies. Nat. Immunol. 24, 1994\u20132007 (2023).","journal-title":"Nat. Immunol."},{"key":"10149_CR14","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.3389\/fimmu.2019.01205","volume":"10","author":"W Hu","year":"2019","unstructured":"Hu, W., Wang, G., Huang, D., Sui, M. & Xu, Y. Cancer immunotherapy based on natural killer cells: current progress and new opportunities. Front. Immunol. 10, 1205 (2019).","journal-title":"Front. Immunol."},{"key":"10149_CR15","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/s41434-021-00246-w","volume":"28","author":"N Albinger","year":"2021","unstructured":"Albinger, N., Hartmann, J. & Ullrich, E. Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany. Gene Ther. 28, 513\u2013527 (2021).","journal-title":"Gene Ther."},{"key":"10149_CR16","doi-asserted-by":"publisher","first-page":"5899","DOI":"10.3390\/ijms22115899","volume":"22","author":"E Wrona","year":"2021","unstructured":"Wrona, E., Borowiec, M. & Potemski, P. CAR-NK cells in the treatment of solid tumors. Int. J. Mol. Sci. 22, 5899 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"10149_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.102619","volume":"24","author":"AL Portillo","year":"2021","unstructured":"Portillo, A. L. et al. Expanded human NK cells armed with CAR uncouple potent anti-tumor activity from off-tumor toxicity against solid tumors. iScience 24, 102619 (2021).","journal-title":"iScience"},{"key":"10149_CR18","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","volume":"19","author":"N Shimasaki","year":"2020","unstructured":"Shimasaki, N., Jain, A. & Campana, D. NK cells for cancer immunotherapy. Nat. Rev. Drug Discov. 19, 200\u2013218 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"10149_CR19","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1158\/2159-8290.CD-20-0655","volume":"11","author":"B Cozar","year":"2021","unstructured":"Cozar, B. et al. Tumor-infiltrating natural killer cells. Cancer Discov. 11, 34\u201344 (2021).","journal-title":"Cancer Discov."},{"key":"10149_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003894","volume":"9","author":"I Christodoulou","year":"2021","unstructured":"Christodoulou, I. et al. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities. J. Immunother. Cancer 9, e003894 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"10149_CR21","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41586-023-06945-1","volume":"626","author":"E Vivier","year":"2024","unstructured":"Vivier, E. et al. Natural killer cell therapies. Nature 626, 727\u2013736 (2024).","journal-title":"Nature"},{"key":"10149_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004244","volume":"10","author":"PL Bernard","year":"2022","unstructured":"Bernard, P. L. et al. Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity. J. Immunother. Cancer 10, e004244 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"10149_CR23","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/ni.3470","volume":"17","author":"RB Delconte","year":"2016","unstructured":"Delconte, R. B. et al. CIS is a potent checkpoint in NK cell-mediated tumor immunity. Nat. Immunol. 17, 816\u2013824 (2016).","journal-title":"Nat. Immunol."},{"key":"10149_CR24","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.stem.2020.05.008","volume":"27","author":"H Zhu","year":"2020","unstructured":"Zhu, H. et al. Metabolic reprograming via deletion of CISH in human iPSC-derived NK cells promotes in vivo persistence and enhances anti-tumor activity. Cell Stem Cell 27, 224\u2013237 (2020).","journal-title":"Cell Stem Cell"},{"key":"10149_CR25","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3389\/fimmu.2020.00075","volume":"11","author":"RB Delconte","year":"2020","unstructured":"Delconte, R. B. et al. NK cell priming from endogenous homeostatic signals is modulated by CIS. Front. Immunol. 11, 75 (2020).","journal-title":"Front. Immunol."},{"key":"10149_CR26","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s13046-023-02770-6","volume":"42","author":"T Nakazawa","year":"2023","unstructured":"Nakazawa, T. et al. CIS deletion by CRISPR\/Cas9 enhances human primary natural killer cell functions against allogeneic glioblastoma. J. Exp. Clin. Cancer Res. 42, 205 (2023).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10149_CR27","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.3390\/ijms22073489","volume":"22","author":"T Morimoto","year":"2021","unstructured":"Morimoto, T. et al. CRISPR\u2013Cas9-Mediated TIM3 knockout in human natural killer cells enhances growth inhibitory effects on human glioma cells. Int. J. Mol. Sci. 22, 3489 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"10149_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1231916","volume":"14","author":"A Mac Donald","year":"2023","unstructured":"Mac Donald, A. et al. KLRC1 knockout overcomes HLA-E-mediated inhibition and improves NK cell antitumor activity against solid tumors. Front. Immunol. 14, 1231916 (2023).","journal-title":"Front. Immunol."},{"key":"10149_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114867","volume":"43","author":"Y Qin","year":"2024","unstructured":"Qin, Y. et al. Developing enhanced immunotherapy using NKG2A knockout human pluripotent stem cell-derived NK cells. Cell Rep. 43, 114867 (2024).","journal-title":"Cell Rep."},{"key":"10149_CR30","doi-asserted-by":"publisher","first-page":"5896","DOI":"10.3390\/ijms25115896","volume":"25","author":"T Nakazawa","year":"2024","unstructured":"Nakazawa, T. et al. Characterization of HIF-1\u03b1 knockout primary human natural killer cells including populations in allogeneic glioblastoma. Int. J. Mol. Sci. 25, 5896 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"10149_CR31","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.immuni.2020.05.001","volume":"52","author":"J Ni","year":"2020","unstructured":"Ni, J. et al. Single-cell RNA sequencing of tumor-infiltrating NK cells reveals that inhibition of transcription factor HIF-1\u03b1 unleashes NK cell activity. Immunity 52, 1075\u20131087 (2020).","journal-title":"Immunity"},{"key":"10149_CR32","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/s41587-024-02282-4","volume":"43","author":"L Peng","year":"2025","unstructured":"Peng, L. et al. In vivo AAV\u2013SB-CRISPR screens of tumor-infiltrating primary NK cells identify genetic checkpoints of CAR-NK therapy. Nat. Biotechnol. 43, 752\u2013761 (2025).","journal-title":"Nat. Biotechnol."},{"key":"10149_CR33","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1038\/s41586-025-09087-8","volume":"643","author":"H Rafei","year":"2025","unstructured":"Rafei, H. et al. CREM is a regulatory checkpoint of CAR and IL-15 signalling in NK cells. Nature 643, 1076\u20131086 (2025).","journal-title":"Nature"},{"key":"10149_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215736","volume":"540","author":"X Zhang","year":"2022","unstructured":"Zhang, X. et al. Gene knockout in cellular immunotherapy: application and limitations. Cancer Lett. 540, 215736 (2022).","journal-title":"Cancer Lett."},{"key":"10149_CR35","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/nature14136","volume":"517","author":"S Konermann","year":"2015","unstructured":"Konermann, S. et al. Genome-scale transcriptional activation by an engineered CRISPR\u2013Cas9 complex. Nature 517, 583\u2013588 (2015).","journal-title":"Nature"},{"key":"10149_CR36","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/imr.13241","volume":"320","author":"X Zhou","year":"2023","unstructured":"Zhou, X., Renauer, P. A., Zhou, L., Fang, S. Y. & Chen, S. Applications of CRISPR technology in cellular immunotherapy. Immunol. Rev. 320, 199\u2013216 (2023).","journal-title":"Immunol. Rev."},{"key":"10149_CR37","doi-asserted-by":"publisher","first-page":"5246","DOI":"10.7150\/thno.34713","volume":"9","author":"H Chen","year":"2019","unstructured":"Chen, H. et al. APLN promotes hepatocellular carcinoma through activating PI3K\/Akt pathway and is a druggable target. Theranostics 9, 5246\u20135260 (2019).","journal-title":"Theranostics"},{"key":"10149_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2024.109983","volume":"755","author":"Q Wang","year":"2024","unstructured":"Wang, Q. et al. APLN promotes the proliferation, migration, and glycolysis of cervical cancer through the PI3K\/AKT\/mTOR pathway. Arch. Biochem. Biophys. 755, 109983 (2024).","journal-title":"Arch. Biochem. Biophys."},{"key":"10149_CR39","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nature23477","volume":"548","author":"SJ Patel","year":"2017","unstructured":"Patel, S. J. et al. Identification of essential genes for cancer immunotherapy. Nature 548, 537\u2013542 (2017).","journal-title":"Nature"},{"key":"10149_CR40","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1111\/febs.16694","volume":"290","author":"A Karagiota","year":"2023","unstructured":"Karagiota, A., Kanoura, A., Paraskeva, E., Simos, G. & Chachami, G. Pyruvate dehydrogenase phosphatase 1 (PDP1) stimulates HIF activity by supporting histone acetylation under hypoxia. FEBS J. 290, 2165\u20132179 (2023).","journal-title":"FEBS J."},{"key":"10149_CR41","doi-asserted-by":"publisher","first-page":"7397250","DOI":"10.1155\/2022\/7397250","volume":"2022","author":"Y Song","year":"2022","unstructured":"Song, Y., Zhang, J., Zhang, L., Zhang, S. & Shen, C. PDP1 promotes cell malignant behavior and is associated with worse clinical features in ovarian cancer patients: evidence from bioinformatics and in vitro level. Comput. Math. Methods Med. 2022, 7397250 (2022).","journal-title":"Comput. Math. Methods Med."},{"key":"10149_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217007","volume":"597","author":"M Yuan","year":"2024","unstructured":"Yuan, M. et al. PDP1 promotes KRAS mutant colorectal cancer progression by serving as a scaffold for BRAF and MEK1. Cancer Lett. 597, 217007 (2024).","journal-title":"Cancer Lett."},{"key":"10149_CR43","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1038\/s41375-023-02041-5","volume":"37","author":"I Alshamleh","year":"2023","unstructured":"Alshamleh, I. et al. PDP1 is a key metabolic gatekeeper and modulator of drug resistance in FLT3-ITD-positive acute myeloid leukemia. Leukemia 37, 2367\u20132382 (2023).","journal-title":"Leukemia"},{"key":"10149_CR44","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","volume":"30","author":"D Marin","year":"2024","unstructured":"Marin, D. et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1\/2 trial. Nat. Med. 30, 772\u2013784 (2024).","journal-title":"Nat. Med."},{"key":"10149_CR45","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s40425-017-0275-9","volume":"5","author":"V Kremer","year":"2017","unstructured":"Kremer, V. et al. Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma. J. Immunother. Cancer 5, 73 (2017).","journal-title":"J. Immunother. Cancer"},{"key":"10149_CR46","doi-asserted-by":"crossref","unstructured":"Sun, Y. et al. Adaptive NK cells exhibit tumor-specific immune memory and cytotoxicity in ovarian cancer. Cancer Immunol. Res. 13, 1080\u20131097 (2025).","DOI":"10.1158\/2326-6066.CIR-24-0852"},{"key":"10149_CR47","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/leu.2017.226","volume":"32","author":"E Liu","year":"2018","unstructured":"Liu, E. et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia 32, 520\u2013531 (2018).","journal-title":"Leukemia"},{"key":"10149_CR48","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu, E. et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N. Engl. J. Med. 382, 545\u2013553 (2020).","journal-title":"N. Engl. J. Med."},{"key":"10149_CR49","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1186\/s13287-021-02377-8","volume":"12","author":"C Choi","year":"2021","unstructured":"Choi, C. & Finlay, D. K. Optimising NK cell metabolism to increase the efficacy of cancer immunotherapy. Stem Cell Res. Ther. 12, 320 (2021).","journal-title":"Stem Cell Res. Ther."},{"key":"10149_CR50","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40164-024-00522-6","volume":"13","author":"L Egli","year":"2024","unstructured":"Egli, L. et al. CAR T cells outperform CAR NK cells in CAR-mediated effector functions in head-to-head comparison. Exp. Hematol. Oncol. 13, 51 (2024).","journal-title":"Exp. Hematol. Oncol."},{"key":"10149_CR51","first-page":"4048","volume":"61","author":"S Modak","year":"2001","unstructured":"Modak, S., Kramer, K., Gultekin, S. H., Guo, H. F. & Cheung, N. K. Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors. Cancer Res. 61, 4048\u20134054 (2001).","journal-title":"Cancer Res."},{"key":"10149_CR52","doi-asserted-by":"publisher","first-page":"30018","DOI":"10.1074\/jbc.M115.679852","volume":"290","author":"M Ahmed","year":"2015","unstructured":"Ahmed, M. et al. Humanized affinity-matured monoclonal antibody 8H9 has potent antitumor activity and binds to FG loop of tumor antigen B7-H3. J. Biol. Chem. 290, 30018\u201330029 (2015).","journal-title":"J. Biol. Chem."},{"key":"10149_CR53","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1038\/s41587-019-0246-4","volume":"37","author":"L Ye","year":"2019","unstructured":"Ye, L. et al. In vivo CRISPR screening in CD8 T cells with AAV-Sleeping Beauty hybrid vectors identifies membrane targets for improving immunotherapy for glioblastoma. Nat. Biotechnol. 37, 1302\u20131313 (2019).","journal-title":"Nat. Biotechnol."},{"key":"10149_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2009-10-3-r25","volume":"10","author":"B Langmead","year":"2009","unstructured":"Langmead, B., Trapnell, C., Pop, M. & Salzberg, S. L. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 10, R25 (2009).","journal-title":"Genome Biol."},{"key":"10149_CR55","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1101\/gr.238923.118","volume":"29","author":"F Allen","year":"2019","unstructured":"Allen, F. et al. JACKS: joint analysis of CRISPR\/Cas9 knockout screens. Genome Res. 29, 464\u2013471 (2019).","journal-title":"Genome Res."},{"key":"10149_CR56","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/978-1-4939-3578-9_19","volume":"1418","author":"AT Lun","year":"2016","unstructured":"Lun, A. T., Chen, Y. & Smyth, G. K. It\u2019s DE-licious: a recipe for differential expression analyses of RNA-seq experiments using quasi-likelihood methods in edgeR. Methods Mol. Biol. 1418, 391\u2013416 (2016).","journal-title":"Methods Mol. Biol."},{"key":"10149_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0554-4","volume":"15","author":"W Li","year":"2014","unstructured":"Li, W. et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR\/Cas9 knockout screens. Genome Biol. 15, 554 (2014).","journal-title":"Genome Biol."},{"key":"10149_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-020-00809-3","volume":"13","author":"E Kim","year":"2021","unstructured":"Kim, E. & Hart, T. Improved analysis of CRISPR fitness screens and reduced off-target effects with the BAGEL2 gene essentiality classifier. Genome Med. 13, 2 (2021).","journal-title":"Genome Med."},{"key":"10149_CR59","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1101\/gr.245571.118","volume":"29","author":"HH Jeong","year":"2019","unstructured":"Jeong, H. H., Kim, S. Y., Rousseaux, M. W. C., Zoghbi, H. Y. & Liu, Z. Beta-binomial modeling of CRISPR pooled screen data identifies target genes with greater sensitivity and fewer false negatives. Genome Res. 29, 999\u20131008 (2019).","journal-title":"Genome Res."},{"key":"10149_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-017-3938-5","volume":"18","author":"G Jia","year":"2017","unstructured":"Jia, G., Wang, X. & Xiao, G. A permutation-based non-parametric analysis of CRISPR screen data. BMC Genomics 18, 545 (2017).","journal-title":"BMC Genomics"},{"key":"10149_CR61","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1126\/science.aac7041","volume":"350","author":"T Wang","year":"2015","unstructured":"Wang, T. et al. Identification and characterization of essential genes in the human genome. Science 350, 1096\u20131101 (2015).","journal-title":"Science"},{"key":"10149_CR62","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.cell.2017.01.013","volume":"168","author":"T Wang","year":"2017","unstructured":"Wang, T. et al. Gene essentiality profiling reveals gene networks and synthetic lethal interactions with oncogenic Ras. Cell 168, 890\u2013903 (2017).","journal-title":"Cell"},{"key":"10149_CR63","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1158\/2159-8290.CD-16-0154","volume":"6","author":"AJ Aguirre","year":"2016","unstructured":"Aguirre, A. J. et al. Genomic copy number dictates a gene-independent cell response to CRISPR\/Cas9 targeting. Cancer Discov. 6, 914\u2013929 (2016).","journal-title":"Cancer Discov."},{"key":"10149_CR64","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1038\/ng.3984","volume":"49","author":"RM Meyers","year":"2017","unstructured":"Meyers, R. M. et al. Computational correction of copy number effect improves specificity of CRISPR\u2013Cas9 essentiality screens in cancer cells. Nat. Genet. 49, 1779\u20131784 (2017).","journal-title":"Nat. Genet."},{"key":"10149_CR65","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.cell.2015.11.015","volume":"163","author":"T Hart","year":"2015","unstructured":"Hart, T. et al. High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities. Cell 163, 1515\u20131526 (2015).","journal-title":"Cell"},{"key":"10149_CR66","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1158\/2159-8290.CD-17-1119","volume":"8","author":"RJ Sullivan","year":"2018","unstructured":"Sullivan, R. J. et al. First-in-class ERK1\/2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: results of a Phase I dose-escalation and expansion study. Cancer Discov. 8, 184\u2013195 (2018).","journal-title":"Cancer Discov."},{"key":"10149_CR67","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/s43018-025-00940-3","volume":"6","author":"W Lei","year":"2025","unstructured":"Lei, W. et al. Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory\/relapsed large B cell lymphoma: a phase 1 trial. Nat. Cancer 6, 786\u2013800 (2025).","journal-title":"Nat. Cancer"},{"key":"10149_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00660-2","volume":"12","author":"N Albinger","year":"2022","unstructured":"Albinger, N. et al. Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia. Blood Cancer J. 12, 61 (2022).","journal-title":"Blood Cancer J."},{"key":"10149_CR69","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1182\/bloodadvances.2023012202","volume":"8","author":"S Guo","year":"2024","unstructured":"Guo, S. et al. CD70-specific CAR NK cells expressing IL-15 for the treatment of CD19-negative B-cell malignancy. Blood Adv. 8, 2635\u20132645 (2024).","journal-title":"Blood Adv."},{"key":"10149_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52388-1","volume":"15","author":"T Bexte","year":"2024","unstructured":"Bexte, T. et al. CRISPR\/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells. Nat. Commun. 15, 8439 (2024).","journal-title":"Nat. Commun."},{"key":"10149_CR71","doi-asserted-by":"publisher","first-page":"D916","DOI":"10.1093\/nar\/gkaa1087","volume":"49","author":"A Frankish","year":"2021","unstructured":"Frankish, A. et al. Gencode 2021. Nucleic Acids Res. 49, D916\u2013D923 (2021).","journal-title":"Nucleic Acids Res."},{"key":"10149_CR72","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41587-023-01767-y","volume":"42","author":"Y Hao","year":"2024","unstructured":"Hao, Y. et al. Dictionary learning for integrative, multimodal and scalable single-cell analysis. Nat. Biotechnol. 42, 293\u2013304 (2024).","journal-title":"Nat. Biotechnol."},{"key":"10149_CR73","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1016\/j.cell.2019.05.006","volume":"177","author":"JD Welch","year":"2019","unstructured":"Welch, J. D. et al. Single-cell multi-omic integration compares and contrasts features of brain cell identity. Cell 177, 1873\u20131887 (2019).","journal-title":"Cell"},{"key":"10149_CR74","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.1016\/j.cell.2023.07.034","volume":"186","author":"F Tang","year":"2023","unstructured":"Tang, F. et al. A pan-cancer single-cell panorama of human natural killer cells. Cell 186, 4235\u20134251 (2023).","journal-title":"Cell"},{"key":"10149_CR75","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41587-020-0591-3","volume":"38","author":"V Bergen","year":"2020","unstructured":"Bergen, V., Lange, M., Peidli, S., Wolf, F. A. & Theis, F. J. Generalizing RNA velocity to transient cell states through dynamical modeling. Nat. Biotechnol. 38, 1408\u20131414 (2020).","journal-title":"Nat. Biotechnol."},{"key":"10149_CR76","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1038\/nmeth.4463","volume":"14","author":"S Aibar","year":"2017","unstructured":"Aibar, S. et al. SCENIC: single-cell regulatory network inference and clustering. Nat. Methods 14, 1083\u20131086 (2017).","journal-title":"Nat. Methods"},{"key":"10149_CR77","doi-asserted-by":"publisher","first-page":"D674","DOI":"10.1093\/nar\/gkn653","volume":"37","author":"CF Schaefer","year":"2009","unstructured":"Schaefer, C. F. et al. PID: the Pathway Interaction Database. Nucleic Acids Res. 37, D674\u2013D679 (2009).","journal-title":"Nucleic Acids Res."},{"key":"10149_CR78","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417\u2013425 (2015).","journal-title":"Cell Syst."},{"key":"10149_CR79","doi-asserted-by":"publisher","first-page":"17608","DOI":"10.18632\/oncotarget.24807","volume":"9","author":"S Rosskopf","year":"2018","unstructured":"Rosskopf, S. et al. A Jurkat 76 based triple parameter reporter system to evaluate TCR functions and adoptive T cell strategies. Oncotarget 9, 17608\u201317619 (2018).","journal-title":"Oncotarget"}],"updated-by":[{"DOI":"10.1038\/s41586-026-10855-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000}}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10149-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10149-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10149-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T07:01:55Z","timestamp":1784012515000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10149-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":79,"journal-issue":{"issue":"8110","published-print":{"date-parts":[[2026,4,16]]}},"alternative-id":["10149"],"URL":"https:\/\/doi.org\/10.1038\/s41586-026-10149-8","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"assertion":[{"value":"27 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41586-026-10855-3","URL":"https:\/\/doi.org\/10.1038\/s41586-026-10855-3","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A patent application has been filed by Yale University and Cellinfinity Bio related to the data in this study (US patent application no. 63\/624,561; PCT WO2025158400A1). S.C. is a (co)founder of EvolveImmune Tx, Cellinfinity Bio, MagicTime Med and Chen Consulting. The other authors declare no competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}